Results 61 to 70 of about 6,809 (170)

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial [PDF]

Circulation: Heart Failure, 2014
Background— Soluble ST2 (sST2), a biomarker related to inflammation, is associated with outcomes of patients with heart failure. In-depth analyses of the relationship among sST2, changes in sST2, and patient outcomes are reported.
Inder S, Anand, Thomas S, Rector, Michael, Kuskowski, James, Snider, Jay N, Cohn   +4 more
openaire   +2 more sources

Toll/Interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction

Cardiovascular Diabetology, 2011
Background Soluble ST2, a member of the of the Toll/IL-1 superfamily, is a novel biomarker with exceptional predictive value in heart failure and myocardial infarction- related mortality as well as in acute dyspneic states.
Fousteris Evangelos, Melidonis Andreas, Panoutsopoulos George, Tzirogiannis Konstantinos, Foussas Stefanos, Theodosis-Georgilas Anastasios, Tzerefos Stavros, Matsagos Spiridon, Boutati Eleni, Economopoulos Theofanis, Dimitriadis George, Raptis Sotirios   +11 more
doaj   +1 more source

Soluble ST2 in Heart Failure With Preserved Ejection Fraction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundSoluble ST2 is a biomarker that is elevated in certain systemic inflammatory diseases. Comorbidity‐driven microvascular inflammation is postulated to play a key role in heart failure with preserved ejection fraction (HFpEF) pathophysiology, but
Omar F. AbouEzzeddine, Paul M. McKie, Shannon M. Dunlay, Susanna R. Stevens, G. Michael Felker, Barry A. Borlaug, Horng H. Chen, Russell P. Tracy, Eugene Braunwald, Margaret M. Redfield   +9 more
doaj   +1 more source

The Role of Innate Lymphoid Cells in Autoimmune, Allergic and Infectious Diseases: A Systematic Review

Immunology, EarlyView.
This systematic review establishes disease‐specific dysregulations of human innate lymphoid cells (ILCs), demonstrating that an ILC1/ILC3 imbalance compromises mucosal barriers in inflammatory bowel disease, while activated ILC2s drive allergic airway inflammation.
Luan F. Lückmann, Henrique R. Dal‐Pizzol, Louise M. Lückmann, Davi E. Salini, Bruna C. Hasckel, Mikaeli Minati, Bruno Kluwe‐Schiavon, Tatiana Barichello   +7 more
wiley   +1 more source

Soluble ST2 plasma concentrations predict mortality in severe sepsis [PDF]

Intensive Care Medicine, 2010
Patients with sepsis-after surviving the initial hyperinflammatory phase-display features consistent with immunosuppression, including hyporesponsiveness of immunocompetent cells to bacterial agents. Immunosuppression is thought to be facilitated by negative regulators of toll-like receptors, including membrane-bound ST2. We investigated the release of
Hoogerwerf, J.J., Tanck, M.W.T., van Zoelen, M.A.D., Wittebole, X., Laterre, P.F., van der Poll, T.   +5 more
openaire   +5 more sources

Neonatal Exposure to Antibiotics Triggers Obesity in Adulthood by Permanent Microbiota Dysbiosis and Reduction of Adipose Regulatory T Cells

Barrier Immunity, Volume 2, Issue 3, Page 147-164, September 2026.
ABSTRACT Neonatal dysbiosis of the gut microbiota represents a critical environmental factor promoting obesity, but the underlying immunological mechanisms remain unknown. We show here that neonatal treatment of mice with broad‐spectrum antibiotics for the first 3 weeks of life (NeoATB) resulted in the development of obesity and metabolic abnormalities
Peter Zanvit, Junji Xu, Wenjing Yang, Nancy Guo, Tianming Yu, Xue Jiao, Michaela Prochazkova, Wenwen Jin, Na Liu, Sang‐A Park, Cheryl Chia, Daxesh P. Patel, Dunfang Zhang, Nathan Goldberg, Alexander Cain, Frank J. Gonzalez, Yasmine Belkaid, Yingzi Cong, WanJun Chen   +18 more
wiley   +1 more source

Soluble ST2: A new and promising activity marker in ulcerative colitis

World Journal of Gastroenterology, 2011
To correlate circulating soluble ST2 (sST2) levels with the severity of ulcerative colitis (UC) and serum levels of pro-inflammatory cytokines, and to demonstrate the predictive power of sST2 levels for differentiation between active and inactive UC.We recruited 153 patients: 82 with UC, 26 with Crohn's disease (CD) and 43 disease controls [non ...
Díaz Jiménez, David, Núñez, Lucía E., Beltrán, Caroll J., Candia, Enzo, Suazo, Cristóbal, Álvarez Lobos, Manuel, González Burgos, María Julieta, Hermoso Ramello, Marcela, Quera Pino, Rodrigo   +8 more
openaire   +5 more sources

DAMPs, PAMPs, and Alarmins: From Mechanism to Therapy

MedComm, Volume 7, Issue 9, September 2026.
This review synthesizes the expanding biology of PAMPs and DAMPs, from their molecular sources and sensing mechanisms to regulatory networks that govern inflammation and homeostasis. Spanning from classical immune activation to trained immunity and interorgan communication, we highlight the interplay between PAMPs and DAMPs and their context‐dependent ...
Xuanxuan Yu, Yuqin Jin, Baochao Li, Jie Deng, Yiwen Zhou, Jinglun Zhang, Huang Li   +6 more
wiley   +1 more source

Clinical value of soluble ST2 in patients with soft tissue sarcomas: a single center cross-sectional study

Zhongguo aizheng zazhi, 2020
Background and purpose: Soluble suppression of tumorigenicity2 (sST2) is a biomarker of myocardial hypertrophy and myocardial fibrosis. This study aimed to investigate the clinical value of sST2 in patients with soft tissue sarcomas.
LIN Jinyi, WANG Yan, HOU Huiping, ZHOU Yuhong, LIU Tianshu, CHENG Leilei   +5 more
doaj